Zenith Drugs IPO: The category reserved for retail investors was subscribed 6 times, while that for NIIs was booked 80%. In the unlisted market, the company s shares are trading at a premium of Rs 15.
The net proceeds from the public offer will be used for the purchase of machinery and setting up the new plant, existing manufacturing block upgradation, working capital requirements, and general corporate purposes.